Dr. Bannett completed his medical studies at Hebrew University in Israel, and completed pediatrics residency at Tel Aviv University, Asaf Harofeh Medical Center, in 2013. After practicing as a community-based primary care provider and developmental pediatrician in Israel, he came to Stanford in 2016 to complete a clinical fellowship in Developmental-Behavioral Pediatrics (DBP). In fellowship, he engaged in community-based health services research, under the mentorship of Dr. Lynne Huffman and Dr. Heidi Feldman. After fellowship, Dr. Bannett was selected to receive funding through the Department of Pediatrics “Bridge to K” program. In 2021, he completed a master's degree in Health Research and Policy at Stanford and is currently appointed as an instructor in the division of DBP.
- Developmental Behavioral Pediatrics
Honors & Awards
Bridge to K Instructor Support Program, Pediatrics Department, Stanford School of Medicine (2019 - 2022)
Master’s Tuition Program, Maternal & Child Health Research Institute, Stanford (2019 - 2021)
SDBP Research Grant, Society for Developmental and Behavioral Pediatrics, USA (2018 - 2020)
Charles B. Woodruff Endowed Fellow: Clinical Trainee Grant, Maternal & Child Health Research Institute, Stanford (2018 - 2019)
Medical Education: Hebrew University Hadassah Medical School (2008) Israel
Fellowship: Stanford University Developmental-Behavioral Pediatrics Fellowship (2019) CA
Residency: Tel Aviv University, Asaf Harofe Medical Center (2013) Israel
Internship: Rabin Medical Center Beilinson (2008) Israel
Current Research and Scholarly Interests
Yair Bannett, MD, is interested in improving health care delivery in community-based primary care for children with developmental and behavioral (DB) conditions. As an instructor in the Division of Developmental-Behavioral Pediatrics (DBP), he seeks to develop reliable quality measures for assessing management of children with DB conditions in primary care. Current projects include observational studies in the primary care setting, using multi-level analysis of electronic health record (EHR) data to assess management of attention deficit hyperactivity disorder (ADHD) and early identification of autism spectrum disorder and other developmental disabilities. Dr. Bannett is interested in utilizing recent advances in natural language processing technology to better assess quality of care provided by PCPs, with the ultimate goal of implementing clinician- and systems-level interventions aimed at improving health care delivery for children with DB conditions.
Primary Care Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in School-Age Children: Trends and Disparities During the COVID-19 Pandemic.
Journal of developmental and behavioral pediatrics : JDBP
OBJECTIVE: The aim of this study was to assess rates of primary care provider (PCP) diagnosis and treatment of school-age children with attention-deficit/hyperactivity disorder (ADHD) during the COVID-19 pandemic compared with prepandemic years and to investigate disparities in care.METHOD: We retrospectively analyzed electronic health records from all primary care visits (in-person and telehealth) of children aged 6 to 17 years seen between January 2016 and March 2021 in a community-based primary health care network (n = 77,298 patients). Study outcomes are as follows: (1) number of primary care visits, (2) number of visits with ADHD diagnosis (ADHD-related visits), (3) number of PCP prescriptions for ADHD medications, (4) number of patients with first ADHD diagnoses, and (5) number of first PCP prescriptions of ADHD medications. Interrupted time series analysis evaluated changes in rates of study outcomes during 4 quarters of the pandemic year (March 15, 2020-March 15, 2021) compared with prepandemic years (January 1, 2016-March 14, 2020). Patient demographic characteristics during prepandemic and pandemic years were compared.RESULTS: ADHD-related visits dropped in the first quarter of the pandemic year by 33% (95% confidence interval, 22.2%-43.6%), returning to prepandemic rates in subsequent quarters. ADHD medication prescription rates remained stable throughout the pandemic year. Conversely, rates of first ADHD diagnoses and first medication prescriptions remained significantly lower than prepandemic rates. The proportion of ADHD-related visits for patients living in low-income neighborhoods was lower in the pandemic year compared with prepandemic years.CONCLUSION: Ongoing treatment for school-age children with ADHD was maintained during the pandemic, especially in high-income families. Socioeconomic differences in ADHD-related care emphasize the need to improve access to care for all children with ADHD in the ongoing pandemic and beyond.
View details for DOI 10.1097/DBP.0000000000001087
View details for PubMedID 35503665
Behavioral Treatment Recommendation for Preschoolers with ADHD Symptoms: How Are Primary Care Pediatricians Doing?
LIPPINCOTT WILLIAMS & WILKINS. 2022: E123-E124
View details for Web of Science ID 000797424900043
Medication Management of Anxiety and Depression by Primary Care Pediatrics Providers: A Retrospective Electronic Health Record Study.
Frontiers in pediatrics
2022; 10: 794722
Objectives: To describe medication management of children diagnosed with anxiety and/or depression by primary care providers within a primary care network.Study Design/Methods: We performed a retrospective cross-sectional analysis of electronic health record (EHR) structured data from all children seen at least twice in a 4-year observation period within a network of primary care clinics in Northern California. For children who had visit diagnoses of anxiety, depression, anxiety+depression or symptoms characteristic of these conditions, we analyzed the rates and types of medications prescribed. A logistic regression model considered patient variables for the combined sample.Results: Of all patients 6-18 years old (N = 59,484), 4.4% (n = 2,635) had a diagnosis of anxiety only, 2.4% (n = 1,433) depression only, and 1.2% (n = 737) both anxiety and depression (anxiety + depression); 18% of children with anxiety and/or depression had comorbid ADHD. A total of 15.0% with anxiety only (n = 357), 20.5% with depression only (n = 285), and 47.4% with anxiety+depression (n=343) were prescribed a psychoactive non-stimulant medication. For anxiety and depression only, the top three medications prescribed were sertraline, fluoxetine, and citalopram. For anxiety + depression, the top three medications prescribed were citalopram, sertraline, and escitalopram. Frequently prescribed medications also included benzodiazepines. Logistic regression modeling showed that the depression only and anxety + depression categories had increased likelihood of medication prescription. Older age and mental health comorbidities were independently associated with increased likelihood of medication prescription.Conclusions: In this network, ~8% of children carried a diagnosis of anxiety and/or depression. Medication choices generally aligned with current recommendations with the exception of use of benzodiazepines.
View details for DOI 10.3389/fped.2022.794722
View details for PubMedID 35372169
- Rate of Pediatrician Recommendations for Behavioral Treatment for Preschoolers With Attention-Deficit/Hyperactivity Disorder Diagnosis or Related Symptoms. JAMA pediatrics 2021
Diagnosis of Language Delay in the Primary Care Setting: An Electronic Health Record Investigation
LIPPINCOTT WILLIAMS & WILKINS. 2021: S1-S2
View details for Web of Science ID 000670615500016
Continuity of Care by Primary Care Provider in Young Children with Autism
LIPPINCOTT WILLIAMS & WILKINS. 2021: S2
View details for Web of Science ID 000656627200017
Attention-Deficit/Hyperactivity Disorder in 2- to 5-Year-Olds: A Primary Care Network Experience.
To assess (1) rates of primary care provider (PCP) diagnosis of attention-deficit/hyperactivity disorder (ADHD) in young children, (2) documented PCP adherence to ADHD clinical practice guidelines, and (3) patient factors influencing PCP variation in diagnosis and management.Retrospective cohort study of electronic health records from all office visits of children aged 2-5 years, seen ≥2 times between 2015 and 2019, in 10 practices of a community-based primary healthcare network. Outcomes included ADHD diagnosis (symptom or disorder), and adherence to guidelines in (1) comorbidity documentation at or after ADHD diagnosis, (2) ADHD medication choice, and (3) follow-up of medicated patients. Logistic regressions assessed associations between outcomes and patient characteristics.Of 29,408 eligible children, 195 (0.7%) had ADHD diagnoses. Of those, 56% had solely symptom-level diagnoses (e.g., hyperactivity); 54% had documented comorbidities. ADHD medications were prescribed only to 4-5-year-olds (40/195 (21%)); 85% received stimulants as first-line medication; 48% had follow-up visits within 2 months. Likelihood of ADHD diagnosis was higher for children with public or military insurance (OR 1.94; 95% CI 1.40-2.66; OR 3.17; 95% CI 1.93-4.96). Likelihood of comorbidity documentation was lower for older ADHD patients (OR 0.48; 95% CI 0.32-0.71) and higher for those with military insurance (OR 3.11; 95% CI 1.13-9.58).PCPs in this network frequently used symptom-level ADHD diagnoses in 2-5-year-olds; ADHD diagnosis rates were below estimated population prevalence, with evidence for sociodemographic disparities. PCP comorbidity documentation and choice of stimulant medications were consistent with guidelines. Rates of timely follow-up were low.
View details for DOI 10.1016/j.acap.2020.04.009
View details for PubMedID 32360494
Variation in Rate of Attention-Deficit/Hyperactivity Disorder Management by Primary Care Providers.
To describe variation in rates of attention-deficit/hyperactivity disorder (ADHD) management by pediatrics primary care providers (PCPs) and to assess influence of clinician characteristics on variation.Retrospective cohort study of electronic health records (EHR) from all office visits of patients aged 4-17 years seen at least twice between 2015 and 2017 by 73 clinicians in 9 pediatrics practices of a community-based primary healthcare network in California. Outcomes per clinician: (1) % patients seen for ADHD management; (2) % ADHD patients with diagnosed comorbid conditions. Logistic random-effects regression models examined practice- and clinician-level variation.Of 40,323 patients in the cohort, 2,039 (5.1%) carried an ADHD diagnosis, of which 1,142 (56%) received ADHD medication. Percent of patients seen for ADHD management varied by clinician from 0.0 to 8.3% (median 3.0%). After accounting for practice-level variation and patient characteristics (i.e., sex, age, insurance), clinician characteristics explained 28% of clinician variation in ADHD management. ADHD management rate was associated with high percent Full Time Equivalent (OR 1.17; 95% CI 1.07-1.27). Percent of ADHD patients with diagnoses of comorbidities varied by clinician from 0.0 to 100% (median 35%). Association between ADHD management rate and comorbidity diagnosis was minimal (R=0.10).Objective EHR measures showed that PCPs in this network varied widely in their involvement in ADHD management. For most PCPs, % of patients with ADHD and diagnosis of comorbidities was lower than estimated prevalence rates. Exploration of modifiable factors associated with PCP variation is needed to inform strategies for implementation of evidence-based practices.
View details for DOI 10.1016/j.acap.2019.11.016
View details for PubMedID 31794864
Amnesia for traumatic events among recent survivors: a pilot study.
2003; 8 (9): 676-80, 683-5
Traumatic amnesia has been amply documented in the psychoanalytic literature but inconsistently in the research literature.Six trauma were followed prospectively. Survivors were interviewed 7, 30, and 120 days following the traumatic event. Each interview documented in detail their recollections of the day of their trauma.In four subjects who did not develop posttraumatic stress disorder (PTSD), we found brief, stable, and persistent memory gaps, which coincided with the moment of greatest emotional intensity. In two subjects who developed PTSD, we found, in addition to the previous form of amnesia, longer, progressive, and unstable memory gaps.Neurobiological research offers two explanatory mechanisms for the observations: A failure of acquisition of episodic memories may account for the stable deficits seen in all subjects. This could coincide with stress-induced malfunction of the hippocampal declarative memory system. A failure of spontaneous recall may account for the more extended traumatic amnesia that was observed in PTSD patients. This resembles the psychoanalytic description of repression.These preliminary findings suggest that brief, irreversible memory gaps are common in trauma survivors, whereas longer, progressive, and potentially reversible amnesia occurs among survivors who develop PTSD.
View details for DOI 10.1017/s1092852900008865
View details for PubMedID 15079141